𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Patient and tumor characteristics associated with increased mortality in young women (≤40 years) with breast cancer

✍ Scribed by Ankit Bharat; Rebecca L. Aft; Feng Gao; Julie A. Margenthaler


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
72 KB
Volume
100
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Background

The goal of the current study is to identify predictors responsible for mortality disparities between young (≤40 years) and older (>40 years) women with breast cancer.

Methods

From 1998 to 2006, 344 patients ≤40 years were treated for breast cancer. Cox regression models calculated adjusted hazard ratios (aHR) and 95% confidence intervals (CI) to determine differences in breast cancer mortality in women ≤40 years versus >40 years (n = 3,252), controlling for potential confounders in univariate tests.

Results

From 1998 to 2006, 3,596 patients were treated for breast cancer; 9.6% were ≤40 years and 90.4% were >40 years. Young women were more likely to be African‐American, with a family history of breast cancer, diagnosed at advanced stage, and treated by mastectomy (P < 0.05). Tumors in young women were more likely to be bilateral, T2/T3, grade III, ER/PR negative, and lymph‐node positive (P < 0.01). Overall, young women (≤40 years) with breast cancer were more likely to die compared with older women (>40 years) (aHR 1.52, CI 1.37–1.74).

Conclusions

Young women (≤40 years) with breast cancer are diagnosed at a more advanced stage and have tumors with poor prognostic features. Young women (≤40 years) are 52% more likely to die from breast cancer compared to older women (>40 years). J. Surg. Oncol. 2009;100:248–251. © 2009 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Breast-cancer screening with mammography
✍ Organizing Committee; Collaborators; Falun Meeting; Falun; Sweden 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 670 KB

For some years, there has been a perceived need for more information on the effect of screening for breast cancer in women aged 40 to 49. Our approach was to gather the most recent data on screening in this age group, to assess the following quantities: the likely beneffi in mortality terms, measure

TP53 mutations in breast cancer tumors o
✍ Tatiana A. Simão; Fabiana S. Ribeiro; Lídia M. F. Amorim; Rodolpho M. Albano; Ma 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 129 KB 👁 1 views

Somatic mutations in the TP53 gene are the most frequently observed genetic alterations in human malignancies, including breast cancer, which is one of the leading causes of death among women in Brazil. In our study, we determined the frequency and the pattern of TP53 mutations in malignant breast t